Our Shareholders Since 13 March 2014, UCB’s capital amounts to € 583 516 974, divided in 194 505 658 ordinary shares with no nominal value.The main shareholder of UCB is Financière de Tubize SA, a Belgian company listed on Euronext Brussels. The latest shareholding structure of Financière de Tubize SA is available here. Shareholder Structure Investors Percent Financiere de Tubize 36% Treasury shares 2% Wellington 5% Blackrock 5% FMR 7.5% Other Institutional Investors 36% Retail Investors 7% Unidentified 1.5% Source Latest notifications and shareholder identification (as of May 2024), UCB underlying ownership analysis close 62% Free Float Country Percent United States 50% United Kingdom 14% France 10% Belgium 6% Rest of Europe 14% Rest of World 6% Institutional investors: Geographic distribution Shareholders' Meetings The Ordinary General Meeting of Shareholders is held on the last Thursday of April at 11:00 CET. Shareholders' Meeting Archives Please select Shareholders meeting 2024 Shareholders meeting 2023 Shareholders meeting 2022 Shareholders meeting 2021 Shareholders meeting 2020 Shareholders meeting 2019 Shareholders meeting 2018 Shareholders meeting 2017 Select Title Format Download Abolition of UCB bearer shares (ENG) PDF Download Abolition of UCB bearer shares (FR) PDF Download Abolition of UCB bearer shares (NL) PDF Download Shareholding overview Transparency notifications Share repurchase program Notification pursuant to public takeover bids legislation Consensus Estimates based on Visible Alpha consensus1 dated 01.12.2024.Estimates include 15 broker models2 collaborating with Visible Alpha. UCB FY Consensus Earnings Estimates (Average)In € million2023a2024e2025e 2026e2027e2028e2029eNet Sales4,8675,4806,4777,3198,2758,9909,588Revenue5,2525,8296,7947,6528,6139,2979,860Adjusted EBIT6577231,3611,8472,4182,7282,994Adjusted EBITDA1,3491,3882,0252,5203,0753,3943,658Adj. EBITDA ratio25.7%23.8%29.8%32.9%35.7%36.5%37.1%Net Profit3434419741,3601,8092,0652,290Core EPS (€)4.204.187.149.1211.6513.3814.74 UCB FY Consensus Product Sales Estimates (Average)In € million2023a2024e2025e 2026e 2027e 2028e2029eProduct Portfolio Cimzia2,0872,0171,9091,7601,6151,3471,131Bimzelx1485471,2672,0742,9553,7544,385Evenity*60110156201231254268Rystiggo 179325470603678751Zilbrysq 68182308424533609Vimpat394319263224202180168Keppra636575527488454418390Briviact576674748580407307253Neupro 234189162140125113Fintepla226340477614732810853Nayzilam94114132139147140115Potential New Products non-risk adjusted Dapirolizumab pegol 194180126251Staccato alprazolam 30224262106141Bepranemab 145323Minzasolmin 130325doxTM / MT1621 3855100139171*European sales, ex-EU sales booked by Amgen/Astellas 1Disclaimer The information provided by Visible Alpha cited herein provided “as is” and “as available” without warranty of any kind. Use of any Visible Alpha data is at your own risk and Visible Alpha disclaims any liability for use of the Visible Alpha data.Although the information is obtained or compiled from reliable sources Visible Alpha neither can nor does guarantee or make any representation or warranty, either express or implied, as to the accuracy, validity, sequence, timeliness, completeness or continued availability of any information or data, including third-party content, made available herein.In no event shall Visible Alpha be liable for any decision made or action or inaction taken in reliance on any information or data, including third-party content. Visible Alpha further explicitly disclaims, to the fullest extent permitted by applicable law, any warranty of any kind, whether express or implied, including warranties of merchantability, fitness for a particular purpose and non-infringement. 2Contributing brokers BrokerModel dateAlphaValue05-Nov-2024Berenberg17-Jul-2024BNPP Exane31-Jul-2024BofA24-Jul-2024Cowen30-Oct-2024Degroof Petercam27-Sep-2024Deutsche Bank08-Nov-2024HSBC28-Oct-2024ING13-Nov-2024Jefferies06-Nov-2024KBC14-Aug-2024Kepler20-Jun-2024ODDO BHF26-Jul-2024Redburn11-Nov-2024UBS01-Nov-2024 All analyst contacts Dividends The Board intends to continue to sustain a dynamic dividend policy, consistent with the long-term growth prospects of the Company, offering gradual increase in dividend, and as far as possible not to reduce it, irrespective of the short-term income variations. Year Gross Dividend (€) Net Dividend (€) 2019 1.24 0.868 2020 1.27 0.889 2021 1.30 0.91 2022 1.33 0.93 The Board of Directors proposes to pay a gross dividend of € 1.36 per share (gross), to be approved by the annual general meeting of the shareholders.Coupon # 27Ex-dividend: 26 April 2024Record date: 29 April 2024Payment: 30 April 2024Coupon # 27 of UCB shares is payable at € 0.952 net per share after deduction of Belgian withholding tax of 30%*, via our paying agent, KBC Bank NV.* Lower withholding tax rates may be applicable depending on the specific situation of each shareholder. Contact UCB IR Team investor-relations@ucb.com or a specific team member:Antje Witte, Head of Investor RelationsTel: +32 2 559 9414E-mail: Antje.Witte@ucb.com Sahar Yazdian, Investor Relations Lead Tel: +32 2 559 9137E-mail: Sahar.Yazdian@ucb.com Book a virtual meeting Send us feedback UCB IR App
